Shares of Novavax, Inc. (NASDAQ:NVAX – Get Rating) have received a consensus rating of "Hold" from the nine research firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $128.25.
A number of research firms have recently commented on NVAX. JPMorgan Chase & Co. lowered shares of Novavax from a "neutral" rating to an "underweight" rating and cut their price objective for the company from $132.00 to $27.00 in a research report on Thursday. Cowen reduced their target price on Novavax to $110.00 in a research note on Monday, August 15th. B. Riley reduced their target price on Novavax from $181.00 to $171.00 in a research note on Friday, July 22nd. Cowen reduced their target price on Novavax from $150.00 to $110.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 9th. Finally, Cantor Fitzgerald increased their target price on Novavax from $146.00 to $168.00 in a research note on Wednesday, June 8th.
Get Novavax alerts:Novavax Stock Performance
NVAX opened at $21.00 on Thursday. The firm has a market cap of $1.64 billion, a P/E ratio of -1.08, a PEG ratio of 0.10 and a beta of 1.65. The firm has a 50-day moving average of $41.22 and a 200 day moving average of $52.06. Novavax has a fifty-two week low of $20.46 and a fifty-two week high of $257.30.
Novavax (NASDAQ:NVAX – Get Rating) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($6.53) earnings per share for the quarter, missing analysts' consensus estimates of $5.51 by ($12.04). The business had revenue of $186.00 million for the quarter, compared to the consensus estimate of $1.02 billion. Novavax had a negative return on equity of 572.54% and a negative net margin of 114.32%. Novavax's revenue for the quarter was down 37.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($4.75) EPS. Equities research analysts predict that Novavax will post 6.09 earnings per share for the current fiscal year.Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of NVAX. Mascoma Wealth Management LLC purchased a new position in Novavax during the 2nd quarter valued at approximately $27,000. San Luis Wealth Advisors LLC purchased a new position in Novavax during the 1st quarter worth approximately $29,000. Focused Wealth Management Inc purchased a new position in shares of Novavax during the 1st quarter valued at approximately $45,000. Exchange Traded Concepts LLC purchased a new position in shares of Novavax during the 2nd quarter valued at approximately $47,000. Finally, Dixon Hughes Goodman Wealth Advisors LLC purchased a new stake in Novavax in the 1st quarter worth $53,000. Institutional investors own 42.63% of the company's stock.
Novavax Company Profile
(Get Rating)
Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
Featured Stories
- Get a free copy of the StockNews.com research report on Novavax (NVAX)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.